Literature DB >> 8296651

Association between silica exposure and necrotizing crescentic glomerulonephritis with p-ANCA and anti-MPO antibodies: a hospital-based case-control study.

G Gregorini1, A Ferioli, F Donato, P Tira, L Morassi, R Tardanico, L Lancini, R Maiorca.   

Abstract

A hospital-based case-control study was carried out to investigate the association between ANCA positive rapidly progressive glomerulonephritis (RPGN) and occupational exposure to silica dust. All ANCA positive male patients admitted to the Department of Nephrology of the University of Brescia between 1987 and 1992 were enrolled in the study as cases. The controls were pts of the same age, admitted at the Department immediately before or after the cases, affected by other renal diseases. Seven of the 16 cases and one of the 32 controls, had a positive history for jobs exposing to silica dust (relative risk 14; 95% C.I.: 1.7-113.8, p < 0.001). ANCA pattern was p-ANCA with anti-MPO antibodies in 6/7 of exposed pts. The review of renal histology showed a distinctive glomerular lesion consisting in peripheral nodular areas of glomerular sclerosis, in addition to the crescentic necrotizing glomerulonephritis, in 3/6 silica exposed pts, but in none of the unexposed pts.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8296651     DOI: 10.1007/978-1-4757-9182-2_77

Source DB:  PubMed          Journal:  Adv Exp Med Biol        ISSN: 0065-2598            Impact factor:   2.622


  15 in total

Review 1.  The association between silica exposure and development of ANCA-associated vasculitis: systematic review and meta-analysis.

Authors:  José A Gómez-Puerta; Lydia Gedmintas; Karen H Costenbader
Journal:  Autoimmun Rev       Date:  2013-06-29       Impact factor: 9.754

Review 2.  ANCA-associated diseases and silica exposure.

Authors:  G Gregorini; P Tira; J Frizza; P C D'Haese; M M Elseviers; G Nuyts; R Maiorca; M E De Broe
Journal:  Clin Rev Allergy Immunol       Date:  1997       Impact factor: 8.667

3.  Occupational silica exposure and chronic kidney disease.

Authors:  Suma Vupputuri; Christine G Parks; Leena A Nylander-French; Ashli Owen-Smith; Susan L Hogan; Dale P Sandler
Journal:  Ren Fail       Date:  2011-10-27       Impact factor: 2.606

4.  Silicon nephropathy and myeloperoxidase antibodies.

Authors:  A Chevailler; F Carrere; G Renier; D Hurez; J F Subra; P Reboul; P Riberi; C Masson
Journal:  Ann Rheum Dis       Date:  1994-11       Impact factor: 19.103

5.  Anti-neutrophil cytoplasmic antibodies in leprosy.

Authors:  Fernando Luiz Barros Edington; Maria Olívia Amado Ramos Bacellar; Paulo Roberto Machado; Lúcio Barbosa; Eliana Reis; Mitermayer Reis; Mittermayer Barreto Santiago
Journal:  Clin Rheumatol       Date:  2006-03-30       Impact factor: 2.980

6.  Occupational exposures and chronic kidney disease: Possible associations with endotoxin and ultrafine particles.

Authors:  Todd R Sponholtz; Dale P Sandler; Christine G Parks; Katie M Applebaum
Journal:  Am J Ind Med       Date:  2015-11-17       Impact factor: 2.214

Review 7.  The pulmonary physician in critical care * illustrative case 3: pulmonary vasculitis.

Authors:  M Griffith; S Brett
Journal:  Thorax       Date:  2003-06       Impact factor: 9.139

8.  Occupational silica exposure and risk of various diseases: an analysis using death certificates from 27 states of the United States.

Authors:  G M Calvert; F L Rice; J M Boiano; J W Sheehy; W T Sanderson
Journal:  Occup Environ Med       Date:  2003-02       Impact factor: 4.402

9.  Association of silica exposure with anti-neutrophil cytoplasmic autoantibody small-vessel vasculitis: a population-based, case-control study.

Authors:  Susan L Hogan; Glinda S Cooper; David A Savitz; Leena A Nylander-French; Christine G Parks; Hyunsook Chin; Caroline E Jennette; Sofia Lionaki; J Charles Jennette; Ronald J Falk
Journal:  Clin J Am Soc Nephrol       Date:  2007-02-07       Impact factor: 8.237

10.  Silica exposure and systemic vasculitis.

Authors:  Karen B Mulloy
Journal:  Environ Health Perspect       Date:  2003-12       Impact factor: 9.031

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.